- Somatic Mutations of TP53 and Prognostic Factors for Primary Operable Breast Cancer: Correspondence
-
Sookaromdee P, Wiwanitkit V
- KMID: 2537652
- J Breast Cancer.
- 2022 Dec;25(6):522.
- doi: 10.4048/jbc.2022.25.e51
-
- CITED
-
- Close
- SHARE
-
- Close
- Somatic Mutations in Breast Cancer: The Tip of the Iceberg
-
Park JH, Kim LS
- KMID: 2537654
- J Breast Cancer.
- 2022 Dec;25(6):523-524.
- doi: 10.4048/jbc.2022.25.e52
-
- CITED
-
- Close
- SHARE
-
- Close
- Pregnancy After Breast Cancer – Prognostic Safety and Pregnancy Outcomes According to Oestrogen Receptor Status: A Systematic Review
-
Nolan K, Boland MR, Hill AD
- KMID: 2537640
- J Breast Cancer.
- 2022 Dec;25(6):443-453.
- doi: 10.4048/jbc.2022.25.e45
Purpose: Breast cancer is the primary cause of cancer-related death in women. Women diagnosed with estrogen receptor (ER)-positive breast cancer have prolonged treatment durations. Owing to the paucity of research... -
- CITED
-
- Close
- SHARE
-
- Close
- Corrigendum: Increased MelanomaAssociated Antigen C2 Expression Affords Resistance to Apoptotic Deathin Suspension-Cultured Tumor Cells
-
Park D, Han S, Joo H, Ka HI, Soh S, Park J, Yang Y
- KMID: 2537655
- J Breast Cancer.
- 2022 Dec;25(6):525.
- doi: 10.4048/jbc.2022.25.e48
-
- CITED
-
- Close
- SHARE
-
- Close
- Malignant Apocrine Lesions of the Breast: Multimodality Imaging Findings and Biologic Features
-
Lee Hj, Kang SW, Lee JE, Jeong WG, Lee JS, Park MH, Lim HS
- KMID: 2537650
- J Breast Cancer.
- 2022 Dec;25(6):513-521.
- doi: 10.4048/jbc.2022.25.e46
The apocrine morphology of the breast is observed in a broad pathological spectrum, ranging from benign cysts to invasive carcinomas. However, the number of clinical research investigating malignant apocrine lesions... -
- CITED
-
- Close
- SHARE
-
- Close
- Ceramide Synthase 6 Mediates TripleNegative Breast Cancer Response to Chemotherapy Through RhoA- and EGFR-Mediated Signaling Pathways
-
Chen H, He B, Ke F
- KMID: 2537648
- J Breast Cancer.
- 2022 Dec;25(6):500-512.
- doi: 10.4048/jbc.2022.25.e47
Purpose: Limited treatment options and lack of treatment sensitivity biomarkers make the clinical management of triple-negative breast cancer (TNBC) challenging. Ceramide synthase 6 (CERS6) generates ceramides, which are key intermediates... -
- CITED
-
- Close
- SHARE
-
- Close
- Prognostic Value of Neutrophilto-Lymphocyte Ratio and Early Standardized Uptake Value Reduction in Patients With Breast Cancer Receiving Neoadjuvant Chemotherapy
-
Bae SJ, Ahn SG, Ji JH, Chu CH, Kim D, Lee J, Park S, Cha C, Jeong J
- KMID: 2537646
- J Breast Cancer.
- 2022 Dec;25(6):485-499.
- doi: 10.4048/jbc.2022.25.e44
Purpose: We investigated the treatment response and prognosis using the neutrophil-tolymphocyte ratio (NLR) and standardized uptake value (SUV) of 18F-fluorodeoxyglucose positron emission tomography ( 18F-FDG PET) in neoadjuvant settings. Methods: Baseline... -
- CITED
-
- Close
- SHARE
-
- Close
- Bisphosphonates and Prevention of the Perimenopausal Breast Cancer Recurrence: A Systematic Review and Meta-Analysis
-
Sanaat Z, Nouri O, Khanzadeh M, Mostafaei H, Vahed N, Kabiri N, Khoei RAA, Salehi-Pourmehr H
- KMID: 2537642
- J Breast Cancer.
- 2022 Dec;25(6):454-472.
- doi: 10.4048/jbc.2022.25.e39
Purpose: Bisphosphonates (BPs) have a powerful effect on reducing bone resorption and improving the survival of patients with breast cancer. We aimed to investigate the impact of BP treatment on... -
- CITED
-
- Close
- SHARE
-
- Close
- Predicting the Response of Neoadjuvant Chemotherapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer With Axillary Lymph Node Metastasis by Multigene Assay
-
Lee JH, Ryu JM, Ahn JH, Cho SY, Lee SK, Yu J, Chae BJ, Nam SJ, Han J, Lee JE, Kim SW
- KMID: 2537644
- J Breast Cancer.
- 2022 Dec;25(6):473-484.
- doi: 10.4048/jbc.2022.25.e49
Purpose: The GenesWell™ breast cancer test (BCT) is a recently developed multigene assay that predicts the risk of distant recurrence in patients with hormone receptor-positive (HR+) and human epidermal growth... -
- CITED
-
- Close
- SHARE
-
- Close
